Healthcare costs of managing <scp>MAFLD</scp> are mostly driven by hospitalisation and advanced fibrosis: cost‐analysis from a tertiary‐care, multi‐disciplinary <scp>MAFLD</scp> clinic

BACKGROUND AND AIMS: Patients with metabolic (dysfunction)-associated fatty liver disease (MAFLD) are frequently multimorbid, putting upward pressure on healthcare costs compared to other liver diseases. As Australian data are limited on expenditures in managing MAFLD, we evaluated hospital-related costs and predictors of costs in patients managed in a dedicated MAFLD clinic. METHODS: We conducted a retrospective review of adults attending a MAFLD clinic in Melbourne, Australia between January 2017 and December 2020. A control cohort of chronic hepatitis B (CHB) patients provided disease context. We analysed direct healthcare utilisation and costs categorised by specialty, hospital setting and fibrosis stage. Multivariate Poisson regression identified independent predictors of increased healthcare utilisation. Multivariate linear regression analysis identified independent predictors of healthcare cost. RESULTS: A total of 310 MAFLD and 261 CHB patients were followed up over a median 1.93 vs 4.06 years (P < 0.001). Advanced fibrosis/cirrhosis (F3-4) represented 26% MAFLD patients and 9% CHB patients accounting for 54.9% and 18.2% total expenditure respectively. Inpatient utility was greater in MAFLD compared to CHB (6.1% vs 0.4%, P < 0.001), as was proportion of hospitalisation costs (48.3% vs 0.8%, P < 0.001). Independent predictors of cost in MAFLD were obstructive sleep apnea (P < 0.01), cardiovascular disease (P = 0.04) and F3-4 (P < 0.001), which also predicted liver-related outpatient appointments and radiology (P < 0.001 for both). CONCLUSIONS: The greatest healthcare-related costs for MAFLD clinic patients are incurred through hospitalisation, with F3-4 predicting a disproportionately high economic burden. Our findings demonstrate the association between metabolic comorbidities and liver disease progression in MAFLD, highlighting a research gap of integrated care provision to optimise resource allocation.

Authors

Institutions

Publication Details

Journal
Internal Medicine Journal
Published
2026-05-21
DOI
https://doi.org/10.1111/imj.70469
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Healthcare costs of managing MAFLD are mostly driven by hospitalisation and advanced fibrosis: cost‐analysis from a tertiary‐care, multi‐disciplinary MAFLD clinic

Carmela Cosentino, Karl Vaz, Tobie Abrahams, John Lubel et al.
Internal Medicine Journal
Liver Disease Diagnosis and Treatment
article

Healthcare costs of managing MAFLD are mostly driven by hospitalisation and advanced fibrosis: cost‐analysis from a tertiary‐care, multi‐disciplinary MAFLD clinic

Carmela Cosentino, Karl Vaz, Tobie Abrahams, John Lubel, Ammar Majeed, William Kemp, Stuart K Roberts, Natalie Ngu
article en

Abstract

BACKGROUND AND AIMS: Patients with metabolic (dysfunction)-associated fatty liver disease (MAFLD) are frequently multimorbid, putting upward pressure on healthcare costs compared to other liver diseases. As Australian data are limited on expenditures in managing MAFLD, we evaluated hospital-related costs and predictors of costs in patients managed in a dedicated MAFLD clinic. METHODS: We conducted a retrospective review of adults attending a MAFLD clinic in Melbourne, Australia between January 2017 and December 2020. A control cohort of chronic hepatitis B (CHB) patients provided disease context. We analysed direct healthcare utilisation and costs categorised by specialty, hospital setting and fibrosis stage. Multivariate Poisson regression identified independent predictors of increased healthcare utilisation. Multivariate linear regression analysis identified independent predictors of healthcare cost. RESULTS: A total of 310 MAFLD and 261 CHB patients were followed up over a median 1.93 vs 4.06 years (P < 0.001). Advanced fibrosis/cirrhosis (F3-4) represented 26% MAFLD patients and 9% CHB patients accounting for 54.9% and 18.2% total expenditure respectively. Inpatient utility was greater in MAFLD compared to CHB (6.1% vs 0.4%, P < 0.001), as was proportion of hospitalisation costs (48.3% vs 0.8%, P < 0.001). Independent predictors of cost in MAFLD were obstructive sleep apnea (P < 0.01), cardiovascular disease (P = 0.04) and F3-4 (P < 0.001), which also predicted liver-related outpatient appointments and radiology (P < 0.001 for both). CONCLUSIONS: The greatest healthcare-related costs for MAFLD clinic patients are incurred through hospitalisation, with F3-4 predicting a disproportionately high economic burden. Our findings demonstrate the association between metabolic comorbidities and liver disease progression in MAFLD, highlighting a research gap of integrated care provision to optimise resource allocation.

Internal Medicine Journal
Monash Health (AU), Alfred Health (AU), Monash University (AU)
Openalex Percentile: Top 6%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.